Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL706413 | 0.76 | ILK (0.46) | APP | |
| SCHEMBL2057021 | 0.71 | KDM4E (0.36) | — | |
| SCHEMBL6045301 | 0.69 | ALDH1A1 (0.43) | — | |
| SCHEMBL29013347 | 0.69 | APP (0.42) | APPMAPKAPK2HSD17B1HSD17B2CYP19A1 | |
| SCHEMBL5320905 | 0.67 | NPC1 (0.50) | — | |
| SCHEMBL14358953 | 0.67 | — | — | |
| SCHEMBL3850573 | 0.66 | APP (0.44) | APPKCNH2HSD17B1HSD17B2CYP19A1 | |
| SCHEMBL29732980 | 0.66 | APP (0.63) | APPHSD17B1HSD17B2CYP19A1CA1 | |
| SCHEMBL845603 | 0.66 | APP (0.63) | APPHSD17B1HSD17B2CYP19A1CA1 | |
| SCHEMBL5303342 | 0.65 | ALDH1A1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443124-A1 | SUBSTITUTED -1,3,8-TRIAZASPIRO[4.5]DECANE-2,4-DIONES | Merck Sharp & Dohme Corp. (US) | 2012-04-25 | — | — | EP | disclosed |
| US-8058305-B2 | Pyrrolidine derivatives as prostaglandin modulators | MERCK SERONO SA (CH) | 2011-11-15 | — | — | US | disclosed |
| WO-2010147776-A1 | SUBSTITUTED -1,3,8-TRIAZASPIRO[4.5]DECANE-2,4-DIONES | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | disclosed |
| US-20090292000-A1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | LABORATOIRES SERONO S.A. (CH) | 2009-11-26 | — | — | US | disclosed |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) | 2007-02-22 | — | — | US | disclosed |
| EP-1725526-A2 | METHOD FOR PREPARING PYRROLIDINE OXIMES | Applied Research Systems ARS Holding N.V. (AN) | 2006-11-29 | — | — | EP | disclosed |
| EP-1620402-A1 | CYCLIC QUATERNARY AMINO DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | Celltech R & D Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005082848-A2 | METHOD FOR PREPARING PYRROLIDINE OXIMES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-09-09 | — | — | WO | disclosed |
| WO-2004094381-A1 | CYCLIC QUATERNARY AMINO DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CELLTECH R & D LIMITED (GB) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | CBR3, INSR, CS | APP 4678/4885MAPKAPK2 3239/4885KCNH2 398/4885 |
| US-20090292000-A1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | PGF, PTGIS, PDE5A | APP 2287/4885MAPKAPK2 2648/4885KCNH2 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.